Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation
source: pixabay.com

Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation

Medical studies are crucial players in the journey to develop new and more efficacious treatment options for patients with rare diseases. On June 10, 2021, Vertex Pharmaceuticals Incorporated ("Vertex") shared…

Continue Reading Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation